Art. -Nr.: HY-16752

Relebactam

(Synonyms: MK-7655)

31 Cited Publications

Kundenbewertung

Based on 31 publication(s) in Google Scholar

Relebactam is a diazabicyclooctane inhibitor with activity against a wide spectrum of β-lactamases, including class A (extended-spectrum β-lactamases and KPC) and class C (AmpC) enzymes. Relebactam shows antibacterial activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 1174018-99-5
Formel: C₁₂H₂₀N₄O₆S
Molecular Weight:348.38

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Relebactam Chemical Structure

CAS. Nr.: 1174018-99-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Clinical Trial
Chemical Information
Publications (31)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen :

In Vitro

Relebactam combine with Imipenem demonstrates activity against KPC-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa^[1].
Relebactam shows limited inhibition of Class D-producing bacteria and has antipseudomonal activity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1174018-99-5
Appearance Solid
Molecular Weight 348.38
Formel C₁₂H₂₀N₄O₆S
Color White to off-white
SMILES

O=S(ON1[C@]2([H])CC[C@@H](C(NC3CCNCC3)=O)[N@@](C2)C1=O)(O)=O
Synonyms

MK-7655
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (31)

All Microbiological AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Int J Antimicrob Agents

In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022. [Abstract]

2025 Jun 4:107550. PMID: 40480535
Int J Antimicrob Agents

MultiRapid ATB NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. [Abstract]

2024 May 14:107206. PMID: 38754526

Relebactam purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2024 May 14:107206. [Abstract]

The MultiRapid ATB NP test. Column D shows the solution with imipenem–relebactam (IPR, 12/4 mg/L);. Reference strain Escherichia coli ATCC 25922 was inoculated in wells A1–F1; Positive control resistant to all the antibiotics was inoculated in wells A2–F2; First tested strain (resistant to CZA, MEV, and IPR) was inoculated in wells A3–F3; Second tested strain (resistant to CZA and FDC) was inoculated in wells A4–F4; and NaCl 0.85% was inoculated in wells A5–F5. Bacterial growth is shown by a colour change of the medium from red to yellow.
Int J Antimicrob Agents

In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. [Abstract]

2022 Nov-Dec;60(5-6):106669. PMID: 36064079

Relebactam purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. [Abstract]

The MICs of seven β-lactams with relebactam 8 mg/L against M. abscessus.

Relebactam purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. [Abstract]

The MICs of seven β-lactams with relebactam 8 mg/L against M. massiliense.
Antibiotics (Basel)

Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]

2021 Nov 3;10(11):1341. PMID: 34827279

Relebactam purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]

Twenty-four-hour time–kill curves of aztreonam (ATM) and relebactam (REL), alone and in combination, on: C. amalonaticus N18; K. pneumoniae KL 12 SG; K. pneumoniae LC954/14.
Antimicrob Agents Chemother

Improved hydrolysis of piperacillin by OXA-48-like R214G variants, a selective advantage under piperacillin-tazobactam exposure. [Abstract]

2026 Jun 3;70(6):e0126725. PMID: 42053451
Antimicrob Agents Chemother

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]

2024 Nov 6;68(11):e0077524. PMID: 39365068
Antimicrob Agents Chemother

Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli. [Abstract]

2024 Aug 19:e0069324. PMID: 39158279
Antimicrob Agents Chemother

In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. [Abstract]

2023 Dec 14;67(12):e0034623. PMID: 37971240
Antimicrob Agents Chemother

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]

2023 Jul 18;67(7):e0033923. PMID: 37255469
Antimicrob Agents Chemother

Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology. [Abstract]

2023 Jun 15;67(6):e0160322. PMID: 37199612

Relebactam purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. [Abstract]

Difference between whole cells and isolated PBPs fraction unbound. P. aeruginosa PAO1 cultures (whole cells) and PBP-containing membrane preparations (isolated) were incubated for 15, 30, and 60 min in the presence of relebactam (REL), and afterwards isolated PBPs labeled with 25 μM Boc-FL.
Antimicrob Agents Chemother

Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. [Abstract]

2020 Nov 17;64(12):e00297-20. PMID: 32928733
Antimicrob Agents Chemother

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens. [Abstract]

2020 Mar 24;64(4):e02255-19. PMID: 31932381
Sci Rep

Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. [Abstract]

2022 Oct 7;12(1):16814. PMID: 36207358
ACS Infect Dis

3- O-Substituted Quercetin: an Antibiotic-Potentiating Agent against Multidrug-Resistant Gram-Negative Enterobacteriaceae through Simultaneous Inhibition of Efflux Pump and Broad-Spectrum Carbapenemases. [Abstract]

2024 May 10;10(5):1624-1643. PMID: 38652574
Microbiol Spectr

In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients. [Abstract]

2023 Dec 12;11(6):e0304723. PMID: 37982634
Microbiol Spectr

Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae. [Abstract]

2023 Jun 15;11(3):e0069223. PMID: 37093051
Microbiol Spectr

PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. [Abstract]

2023 Feb 14;11(1):e0303822. PMID: 36475840
ACS Infect Dis

Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans. [Abstract]

2021 Apr 9;7(4):826-837. PMID: 33723985
J Antimicrob Chemother

Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]

2026 Feb 2;81(3):dkag034. PMID: 41648989
J Antimicrob Chemother

Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]

2025 Nov 5:dkaf408. PMID: 41206063
J Antimicrob Chemother

In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]

2021 Jul 15;76(8):2071-2078. PMID: 33956969
J Antimicrob Chemother

Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]

2021 Feb 11;76(3):653-658. PMID: 33258923
J Glob Antimicrob Resist

In vitro activity of cefiderocol against clinically relevant Gram-negative bacilli collected in China in 2023. [Abstract]

2026 Jun 24:S2213-7165(26)00094-9. PMID: 42342122
J Glob Antimicrob Resist

In vitro and in vivo activities of a novel β-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from China. [Abstract]

2022 Dec:31:1-9. PMID: 35820591
Eur J Clin Microbiol Infect Dis

In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. [Abstract]

2025 Mar;44(3):571-585. PMID: 39704920
Eur J Clin Microbiol Infect Dis

In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. [Abstract]

2025 Feb;44(2):277-284. PMID: 39589655
Infect Drug Resist

Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance of Mycobacterium abscessus to Imipenem. [Abstract]

2020 Aug 18;13:2883-2890. PMID: 32903882
Diagn Microbiol Infect Dis

Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa. [Abstract]

2024 Dec;110(4):116474. PMID: 39191152
bioRxiv

2025 January 21.
Res Sq

2024 Nov 26.
bioRxiv

2021 Mar 13.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 175 mg/mL (502.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (143.52 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8704 mL

14.3521 mL

28.7043 mL

5 mM

0.5741 mL

2.8704 mL

5.7409 mL

10 mM

0.2870 mL

1.4352 mL

2.8704 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 25 mg/mL (71.76 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lapuebla A, et al. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31. [Content Brief]

[2]. Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015 Nov;46(5):483-93. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.8704 mL	14.3521 mL	28.7043 mL	71.7607 mL
	5 mM	0.5741 mL	2.8704 mL	5.7409 mL	14.3521 mL
	10 mM	0.2870 mL	1.4352 mL	2.8704 mL	7.1761 mL
	15 mM	0.1914 mL	0.9568 mL	1.9136 mL	4.7840 mL
	20 mM	0.1435 mL	0.7176 mL	1.4352 mL	3.5880 mL
	25 mM	0.1148 mL	0.5741 mL	1.1482 mL	2.8704 mL
	30 mM	0.0957 mL	0.4784 mL	0.9568 mL	2.3920 mL
	40 mM	0.0718 mL	0.3588 mL	0.7176 mL	1.7940 mL
	50 mM	0.0574 mL	0.2870 mL	0.5741 mL	1.4352 mL
	60 mM	0.0478 mL	0.2392 mL	0.4784 mL	1.1960 mL
	80 mM	0.0359 mL	0.1794 mL	0.3588 mL	0.8970 mL
	100 mM	0.0287 mL	0.1435 mL	0.2870 mL	0.7176 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Relebactam

31 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Relebactam

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Relebactam

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (31)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Relebactam

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Relebactam

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (31)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Relebactam Related Classifications

HY-16752 Related Classifications